Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Terminated Nitrosamine impurity Major Pharmaceuticals NDC 0904-6390-61 D-1466-2019
Class II · Moderate risk

Cephalexin for Oral Suspension USP 250mg/5 mL

CGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven bag) of sucrose (an excipient) used in the finished product.

Terminated Packaging defect Lupin Pharmaceuticals Inc. NDC 68180-441-01 D-0423-2019
Class II · Moderate risk

HCG liquid

Lack of sterility assurance.

Terminated Sterility / contamination Hiers Enterprises, LLC dba Northwest Compounding Pharmacy D-0395-2019

Recalls by year